BioNexus Gene Lab Corp (BGLC) financial statements (2022 and earlier)

Company profile

Business Address 10-2 TOWER B, VERTICAL BUSINESS SUITE,
KUALA LUMPUR, 59200
State of Incorp. WY
Fiscal Year End December 31
SIC 8071 - Medical Laboratories (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 2,788366
Cash and cash equivalents 2,788366
Receivables 23
Inventory, net of allowances, customer advances and progress billings 1,1768
Inventory 1,1768
Other undisclosed current assets 4,019506
Total current assets: 7,985883
Noncurrent Assets
Operating lease, right-of-use asset 6324
Property, plant and equipment 1,786313
Other undisclosed noncurrent assets 28212
Total noncurrent assets: 2,130349
TOTAL ASSETS: 10,1151,231
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 3,171 
Accounts payable 3,171 
Debt 4632
Other undisclosed current liabilities 15719
Total current liabilities: 3,37452
Noncurrent Liabilities
Long-term debt and lease obligation 7857
Finance lease, liability 3545
Operating lease, liability 4212
Other undisclosed noncurrent liabilities 2 
Total noncurrent liabilities: 8057
Total liabilities: 3,453109
Stockholders' equity
Stockholders' equity attributable to parent 6,6621,122
Common stock 10,7806,485
Additional paid in capital (5,012)(5,012)
Accumulated other comprehensive income (loss) 134(17)
Retained earnings (accumulated deficit) 761(333)
Total stockholders' equity: 6,6621,122
TOTAL LIABILITIES AND EQUITY: 10,1151,231

Income statement (P&L) ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
Revenues 11,390127
Other income 88725
Cost of revenue (9,671) 
Other undisclosed gross profit  (71)
Gross profit: 1,72056
Operating expenses (1,333)315
Other undisclosed operating income (loss) 887(647)
Operating income (loss): 1,274(276)
Nonoperating income 11429
Investment income, nonoperating (37) 
Foreign currency transaction gain, before tax 151 
Other nonoperating income  29
Income (loss) from continuing operations before income taxes: 1,387(246)
Income tax expense (benefit) 1(25)
Income (loss) before gain (loss) on sale of properties: 1,389(271)
Other undisclosed net income (loss) (294)25
Net income (loss) available to common stockholders, diluted: 1,094(246)

Comprehensive Income ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
Net income (loss): 1,094(246)
Comprehensive income (loss): 1,094(246)
Other undisclosed comprehensive income, net of tax, attributable to parent 15110
Comprehensive income (loss), net of tax, attributable to parent: 1,245(237)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: